Treating critically ill COVID-19 patients with a combination of lopinavir (LPV) and ritonavir (RTV) is associated with a significant risk of bradycardia, according to new research out of France.
Treating critically ill COVID-19 patients with a combination of lopinavir (LPV) and ritonavir (RTV) is associated with a significant risk of bradycardia, according to new research out of France.